Neusoft said its NeuSight PET/CT device won FDA approval in the U.S. and won CE Mark approval in the European Union in 2015. The newly launched device offers high quality diagnostic images with fast post processing speeds, the company said.
“As a leading medical equipment provider, Neusoft Medical Systems set software technology as our core. We have continuously contributing software and product engineering innovation to China’s medical industry for more than 20 years. The launch of NeuSight PET/CT is a new breakthrough for Neusoft in high-end medical equipment. Looking forward, we will make great efforts in innovation and operational excellence to offer high-quality medical products and services worldwide,” CEO Mr. Patrick Wu said in a press release.
Neusoft said while it previously collaborated with cardiac PET pioneer Positron in the U.S., it now owns Positron and its more than 20 PET installations in the U.S.
R&D for the NeuSight scanner began in 2012, and 4 PET/CT prototypes passed testing and verification in 2014.